Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
Lise Willems(Hôpital Cochin), Didier Bouscary(Université Paris Cité), N. Neveux(Hôpital Cochin), Alexa S. Green(Délégation Paris 5), Olivier Kosmider(Centre National de la Recherche Scientifique), Patrick Mayeux(Université Paris Cité), Alain Schmitt(Institut de Microbiologie de la Méditerranée), Mireille Lambert(Inserm), Arnaud Jacquel(Inserm), Norbert Ifrah(Institut National du Cancer), Patrick Auberger(Inserm), Thiago Trovati Maciel(Inserm), Nicolas Chapuis(Délégation Paris 5), Laury Poulain(Inserm), Valérie Bardet(Délégation Paris 5), Ivan Cruz Moura(Inserm), Nathalie Jacque(Institut Cochin), Catherine Lacombe(Centre National de la Recherche Scientifique), Madalina Uzunov(Sorbonne Université), Isabelle Radford‐Weiss(Hôpital Necker-Enfants Malades), Jérôme Tamburini(Centre National de la Recherche Scientifique)
Cited by 286
Related Papers
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
|Oncogene|2008|852
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
|Cancer Research|2011|620
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543